BioSpace News Archive

EpimAb Biotherapeutics , an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today presented preclinical data at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II. The data presented in the poster titled, “ EMB-01: An innovative bispecific antibody targeting EGFR and c

RSIP Vision, a global leader in artificial intelligence (AI) and computer vision technology, announced today a new set of AI-based medical ultrasound modules.

Xencor Presents Data from Four Preclinical XmAb ® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

AveXis, a Novartis company, today announced the European Commission (EC) granted conditional approval for Zolgensma® (onasemnogene abeparvovec) for the treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1; or for patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to three copies of the SMN2 gene.

Pathnostics, a leading diagnostic solutions company, announced today the publication of ground-breaking research that demonstrates the fundamental impact that bacterial interactions have on antibiotic susceptibility results.

AveXis, a Novartis company, today announced a one-time infusion of Zolgensma® (onasemnogene abeparvovec-xioi) showed rapid, significant and clinically meaningful therapeutic benefit in patients with spinal muscular atrophy (SMA) across a range of studies, including in patients treated presymptomatically, and sustained durability in patients now up to five years post-dosing and some patients more than five years of age.

Gene editing of engineered natural killer cells contributed to enhanced cell persistence and tumor killing Combination of engineered natural killer cells and engineered T cells demonstrated potential to achieve improved tumor control, optimized cell proliferation and moderate levels of cytokine accumulation SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell thera

- Proof of concept for both agonistic and ligand-blocking TNFR2 targeting antibodies - Both antibodies showed significant antitumor activity in several immunocompetent models - TNFR2 targeting antibodies induce tumor-specific T cell responses, regress large tumors and synergize with anti-PD-1 - Phase I clinical trial with BI-1808 expected to start before the end of 2020 - Data on BI-1808 and BI-1910 presented at AACR Virtual Session II

Collaboration between the transplant community, industry, and regulatory agencies develops biomarker aimed to streamline the development of novel therapies intended to improve long-term outcomes for kidney transplant recipients.

Public health law developed as a response to potential bioterrorism as with weaponized smallpox.